How much does Odevixibat cost? List of price information and how to obtain it

Odevixibat (Odevixibat) is an oral small molecule drug used to treat rare hepatobiliary diseases. Its main indication is progressive familial intrahepatic cholestasis (PFIC). Due to its positioning in the orphan drug field, drug prices are generally high. According to public data,Odevixibat The retail price of drugs in countries such as Europe and the United States is very expensive. For example, in the US market, capsules with a specification of 1200 micrograms are 30The selling price of pills can be as high as 8 to 9 US dollars, and the price of a single pill exceeds 2000 US dollars. In the European market, the monthly prices of different specifications ranging from 200micrograms to 1200micrograms range from more than 3,000 euros to 20,000 euros. Overall, this drug is a typical high-priced rare disease treatment drug.

Currently, orvixibat is not available in China, so Chinese patients cannot purchase the drug through ordinary hospital pharmacies for the time being. However, some professional drug service platforms or international pharmacies provide overseas drug purchase services to help patients introduce original drugs through Hong Kong, European and American channels. Since the drug is still a prescription drug, patients need to issue corresponding certification documents after a doctor's evaluation and apply for purchase through formal channels. At the same time, due to the high drug prices, many overseas pharmaceutical companies have established "patient assistance programs" or "compassionate use programs" that can provide eligible patients with a certain percentage of financial exemptions or free medication opportunities.

It is worth mentioning that Odevixibat has obtained rapid review and orphan drug qualification certification from drug regulatory agencies in multiple countries (such as FDA, EMA), which also means that the drug can be included in the medical insurance system or apply for special reimbursement policies in specific countries. In the United States, some assistance programs in cooperation with commercial insurance companies and pharmaceutical companies can reduce patients' personal medication costs to low or even zero. For families of pediatric patients who require long-term treatment, the financial burden will be significantly alleviated if they can successfully apply for medical insurance coverage or subsidy plans.

To sum up, Odevixibat is a high-end orphan drug developed for a small number of people. It is expensive but has clear clinical value. For domestic patients, the drug is currently mainly obtained through overseas channels. They need to carefully evaluate the necessity and financial ability of the drug under the guidance of a doctor, and proactively consult whether there are assistance channels or international drug purchase options available. As the global orphan drug policy gradually improves, the future domestic launch and medical insurance support of orvixibat is also worth looking forward to.

Reference materials:https://www.drugs.com/